219 related articles for article (PubMed ID: 23448847)
1. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia.
Citrome L
CNS Spectr; 2012 Nov; 17 Suppl 1():1-9. PubMed ID: 23448847
[TBL] [Abstract][Full Text] [Related]
2. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
Morrissette DA; Stahl SM
CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
Ereshefsky L; Mascarenas CA
J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
[TBL] [Abstract][Full Text] [Related]
4. Choice of maintenance medication for schizophrenia.
Davis JM; Chen N
J Clin Psychiatry; 2003; 64 Suppl 16():24-33. PubMed ID: 14680416
[TBL] [Abstract][Full Text] [Related]
5. Relapse and rehospitalization: comparing oral and depot antipsychotics.
Schooler NR
J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
[TBL] [Abstract][Full Text] [Related]
6. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.
Citrome L
Int J Clin Pract; 2010 Jan; 64(2):216-39. PubMed ID: 19886879
[TBL] [Abstract][Full Text] [Related]
7. Improving treatment adherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
[TBL] [Abstract][Full Text] [Related]
8. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
[TBL] [Abstract][Full Text] [Related]
9. [Lifelong relapse prevention with antipsychotics in schizophrenia].
Hasan A; Wobrock T
Psychiatr Prax; 2010 Sep; 37(6):268-70. PubMed ID: 20803409
[No Abstract] [Full Text] [Related]
10. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
11. [Psychopharmocotherapy of schizophrenia in forensic and general psychiatry].
Stompe T; Schanda H
Neuropsychiatr; 2011; 25(2):75-84. PubMed ID: 21672506
[TBL] [Abstract][Full Text] [Related]
12. The attitude of patients towards antipsychotic depot treatment.
Heres S; Schmitz FS; Leucht S; Pajonk FG
Int Clin Psychopharmacol; 2007 Sep; 22(5):275-82. PubMed ID: 17690596
[TBL] [Abstract][Full Text] [Related]
13. Depot neuroleptic therapy: clinical considerations.
Remington GJ; Adams ME
Can J Psychiatry; 1995 Apr; 40(3 Suppl 1):S5-11. PubMed ID: 7627927
[TBL] [Abstract][Full Text] [Related]
14. Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications.
Novick D; Haro JM; Bertsch J; Anand H; Jemiai N; Haddad PM
Int Clin Psychopharmacol; 2012 Sep; 27(5):275-82. PubMed ID: 22699789
[TBL] [Abstract][Full Text] [Related]
15. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
Woods SW; Gueorguieva RV; Baker CB; Makuch RW
Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
[TBL] [Abstract][Full Text] [Related]
16. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
[TBL] [Abstract][Full Text] [Related]
17. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
18. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.
Lincoln J; Stewart ME; Preskorn SH
J Psychiatr Pract; 2010 Mar; 16(2):103-14. PubMed ID: 20511734
[TBL] [Abstract][Full Text] [Related]
19. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
Gutwinski S; Müller P; Koller M
Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
[TBL] [Abstract][Full Text] [Related]
20. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM
Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]